文献速递核素与放射性配体治疗肿瘤 PET/CT

[177Lu]Lu-Ibu-DAB-PSMA用于前列腺癌放射性配体治疗的临床转化前临床研究

Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2022-05-30

本研究在无瘤BALB/c裸鼠和PC-3 PIP荷瘤小鼠中比较[177Lu]Lu-Ibu-DAB-PSMA与[177Lu]Lu-PSMA-617及[177Lu]Lu-PSMA-ALB-56的疗效与安全性。结果显示[177Lu]Lu-Ibu-DAB-PSMA抑瘤效果优于[177Lu]Lu-PSMA-617,安全性优于[177Lu]Lu-PSMA-ALB-56,作者认为其可能具有临床转化潜力。

要点

  • [177Lu]Lu-Ibu-DAB-PSMA平均吸收肿瘤剂量约6.6 Gy/MBq,高于[177Lu]Lu-PSMA-617的约4.5 Gy/MBq
  • 2 MBq白蛋白结合型放射性配体治疗组小鼠生存期较[177Lu]Lu-PSMA-617组或未治疗对照组显著延长(p < 0.05)
  • 30 MBq [177Lu]Lu-PSMA-ALB-56组在注射后第10天和第28天出现淋巴细胞和血红蛋白下降,其余两药未见此变化

核心结论

  • [177Lu]Lu-Ibu-DAB-PSMA较[177Lu]Lu-PSMA-617具有显著治疗优势,且安全性优于[177Lu]Lu-PSMA-ALB-56。
  • 基于上述结果,[177Lu]Lu-Ibu-DAB-PSMA可能具有临床转化潜力。

研究设计与样本

  • 在无瘤BALB/c裸鼠中于注射10 MBq放射性配体后第10天和第28天进行观察。
  • 在PC-3 PIP荷瘤小鼠中进行为期十二周的治疗研究,比较各放射性配体至每只小鼠10 MBq(1 nmol)活度的疗效。
  • 在免疫健全小鼠中比较注射30 MBq [177Lu]Lu-Ibu-DAB-PSMA、30 MBq [177Lu]Lu-PSMA-617或[177Lu]Lu-PSMA-ALB-56后的血象。

主要发现

  • 无瘤小鼠各治疗组大多数血浆参数处于同一范围,健康组织病理学检查未见治疗组较未治疗对照组的改变。
  • [177Lu]Lu-Ibu-DAB-PSMA平均吸收肿瘤剂量约6.6 Gy/MBq,高于[177Lu]Lu-PSMA-617的约4.5 Gy/MBq,仅略低于[177Lu]Lu-PSMA-ALB-56的约8.1 Gy/MBq。
  • 与[177Lu]Lu-PSMA-617和[177Lu]Lu-PSMA-ALB-56一致,[177Lu]Lu-Ibu-DAB-PSMA抑制肿瘤生长效果与平均吸收肿瘤剂量增加相符。
  • 注射2 MBq白蛋白结合型放射性配体的小鼠生存期较注射[177Lu]Lu-PSMA-617或未治疗对照组显著延长(p < 0.05)。
  • 接受5 MBq或10 MBq [177Lu]Lu-Ibu-DAB-PSMA或[177Lu]Lu-PSMA-ALB-56治疗的大多数小鼠在研究结束时仍存活。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

[177Lu]Lu-Ibu-DAB-PSMA was previously characterized with moderate albumin-binding properties enabling high tumor accumulation but reasonably low retention in the blood. The aim of this study was to investigate [177Lu]Lu-Ibu-DAB-PSMA in preclinical in vivo experiments and compare its therapeutic efficacy and potential undesired side effects with those of [177Lu]Lu-PSMA-617 and the previously developed [177Lu]Lu-PSMA-ALB-56. BALB/c nude mice without tumors were investigated on Day 10 and 28 after injection of 10 MBq radioligand. It was revealed that most plasma parameters were in the same range for all groups of mice and histopathological examinations of healthy tissue did not show any alternations in treated mice as compared to untreated controls. Based on these results, a therapy study over twelve weeks was conducted with PC-3 PIP tumor-bearing mice for comparison of the radioligands's therapeutic efficacy up to an activity of 10 MBq (1 nmol) per mouse. In agreement with the increased mean absorbed tumor dose, [177Lu]Lu-Ibu-DAB-PSMA (~ 6.6 Gy/MBq) was more effective to inhibit tumor growth than [177Lu]Lu-PSMA-617 (~ 4.5 Gy/MBq) and only moderately less potent than [177Lu]Lu-PSMA-ALB-56 (~ 8.1 Gy/MBq). As a result, the survival of mice treated with 2 MBq of an albumin-binding radioligand was significantly increased (p < 0.05) compared to that of mice injected with [177Lu]Lu-PSMA-617 or untreated controls. The majority of mice treated with 5 MBq or 10 MBq [177Lu]Lu-Ibu-DAB-PSMA or [177Lu]Lu-PSMA-ALB-56 were still alive at study end. Hemograms of immunocompetent mice injected with 30 MBq [177Lu]Lu-Ibu-DAB-PSMA or 30 MBq [177Lu]Lu-PSMA-617 showed values in the same range as untreated controls. This was, however, not the case for mice treated with [177Lu]Lu-PSMA-ALB-56 which revealed a drop in lymphocytes and hemoglobin at Day 10 and Day 28 after injection. The data of this study demonstrated a significant therapeutic advantage of [177Lu]Lu-Ibu-DAB-PSMA over [177Lu]Lu-PSMA-617 and a more favorable safety profile as compared to that of [177Lu]Lu-PSMA-ALB-56. Based on these results, [177Lu]Lu-Ibu-DAB-PSMA may has the potential for a clinical translation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Tschan VJ, Borgna F, Busslinger SD, et al. Preclinical investigations using [177Lu]Lu-Ibu-DAB-PSMA toward its clinical translation for radioligand therapy of prostate cancer. Eur J Nucl Med Mol Imaging. 2022. PMID: 35635566. doi:10.1007/s00259-022-05837-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。